In a year marked by resilience and strategic refocusing, 2seventy bio, Inc. (Nasdaq: TSVT), has made significant strides in its efforts to establish a robust foothold within the biopharmaceutical industry. From achieving impressive sales results for its CAR-T therapy, Abecma, to the sale of its Hemophilia A candidate and gene editing technologies to Novo Nordisk, the company is poised for a promising future.
Abecma Sales Performance
In its recent report, 2seventy bio announced the full-year U.S. sales results for Abecma (idecabtagene vicleucel; ide-cel), in collaboration with Bristol Myers Squibb (BMS). The company recorded U.S. revenue of $242 million for 2024, landing comfortably within its guidance range of $240 to $250 million. This success comes as Abecma continues to expand in the third-line setting for multiple myeloma treatments, signaling growing acceptance and utilization of CAR-T therapies.
Despite facing challenges in the fourth quarter due to increased deferrals of infusions into 2025, 2seventy bio remains optimistic about the future of its CAR-T offerings. Chip Baird, CEO of 2seventy bio, expressed confidence in the continued adoption of CAR-T therapies within existing and emerging treatment paradigms.
Financial Restructuring and Operational Progress
The second quarter of 2024 was transformative for 2seventy bio. The company reported significant financial results, highlighting its strengthened balance sheet following the completion of the sale of its oncology R&D business to Rege. This strategic pivot, according to Baird, has allowed the company to dramatically reduce its cost structure, consequently enhancing its financial position as it prepares for commercial growth in the coming years.
Strategic Partnerships and Future Endeavors
Continuing its trend of strategic alignment, 2seventy bio also made
Comments